Elevated interleukin-6 and interleukin-18 concentrations predict residual inflammatory risk both before and after interleukin-1beta inhibition with canakinumab

31 August 2019 (00:00 - 00:00)
Organised by:
Congress Presentation Part of: Immuno-inflammation as therapeutic target in heart failure Leukocytes, Inflammation, Immunity ESC Premium Access ESC Congress 2019

ESC 365 is supported by

ESC 365 is supported by